| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-08-4285 |
| P698 | PubMed publication ID | 19584292 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| Paul G. Richardson | Q87712102 | ||
| Nikhil V Munshi | Q89228014 | ||
| Melissa Ooi | Q89531124 | ||
| Jana Jakubikova | Q89681431 | ||
| Patrick J Hayden | Q91320499 | ||
| Robert Schlossman | Q114300414 | ||
| Jake E Delmore | Q117224718 | ||
| Constantine S Mitsiades | Q117224720 | ||
| Nicolas Mitsiades | Q117224768 | ||
| P2093 | author name string | Sauveur-Michel Maira | |
| Carlos Garcia-Echeverria | |||
| Joseph Negri | |||
| Douglas W McMillin | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 5835-5842 | |
| P577 | publication date | 2009-07-07 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | |
| P478 | volume | 69 |
| Q91241126 | A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer |
| Q39328713 | Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis |
| Q30582030 | Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer |
| Q42182953 | Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma |
| Q34490880 | Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. |
| Q41914792 | Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. |
| Q36761564 | Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas |
| Q37953476 | Current development of the second generation of mTOR inhibitors as anticancer agents |
| Q37771370 | Development of target-specific treatments in multiple myeloma |
| Q27332333 | Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma |
| Q34810176 | Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma |
| Q41174750 | Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. |
| Q42070616 | Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines |
| Q39084910 | Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation |
| Q38112176 | Emerging pathways as individualized therapeutic target of multiple myeloma. |
| Q37662286 | Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. |
| Q38095958 | Experimental approaches in the treatment of multiple myeloma |
| Q26865162 | Fragile X syndrome and targeted treatment trials |
| Q34291001 | Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas |
| Q38963261 | In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. |
| Q52687754 | Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. |
| Q39593159 | Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide |
| Q40787051 | Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations |
| Q38193070 | Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies |
| Q28071388 | Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q39161442 | Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity |
| Q39395884 | Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity |
| Q37986287 | Latest advances and current challenges in the treatment of multiple myeloma |
| Q37872670 | Mechanisms of mTOR inhibitor resistance in cancer therapy |
| Q28478937 | Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation |
| Q54377413 | Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. |
| Q37910724 | Molecular basis for the actions of Hsp90 inhibitors and cancer therapy |
| Q34773850 | New insights, recent advances, and current challenges in the biological treatment of multiple myeloma |
| Q24628724 | Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy |
| Q34420112 | Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone |
| Q37924637 | Novel therapies in MM: from the aspect of preclinical studies |
| Q39380262 | Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype |
| Q37727180 | PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes |
| Q48263465 | PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. |
| Q36718464 | PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. |
| Q39036088 | PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. |
| Q37779489 | Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies |
| Q37816960 | Preclinical development of molecular-targeted agents for cancer |
| Q90638601 | RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS |
| Q38753307 | Signaling Pathways and Emerging Therapies in Multiple Myeloma |
| Q35740455 | Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma |
| Q35999766 | Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity |
| Q33585280 | Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death |
| Q37353724 | Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. |
| Q36333522 | Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. |
| Q37946702 | Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma |
| Q39210830 | The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma |
| Q36052399 | The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and |
| Q34038031 | The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer |
| Q38960721 | The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. |
| Q38246060 | The future of proteasome inhibitors in relapsed/refractory multiple myeloma. |
| Q35552693 | The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias |
| Q37877729 | The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma |
| Q34500544 | The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma |
| Q39562043 | The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells |
| Q28476644 | The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing |
| Q34218069 | Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma |
| Q38065305 | Understanding the molecular biology of myeloma and its therapeutic implications |
| Q24607170 | Updates of mTOR inhibitors |
| Q47107700 | VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. |
| Q34682072 | Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma |
| Q33394281 | Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study |
| Q37728043 | ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system |
| Q39113506 | m-TOR inhibitors and their potential role in haematological malignancies |
| Q37649634 | mTOR pathway in colorectal cancer: an update |
| Q24633662 | mTOR: from growth signal integration to cancer, diabetes and ageing |
Search more.